S
Seock–Ah –A Im
Researcher at Seoul National University Hospital
Publications - 9
Citations - 610
Seock–Ah –A Im is an academic researcher from Seoul National University Hospital. The author has contributed to research in topics: Population & Breast cancer. The author has an hindex of 6, co-authored 9 publications receiving 489 citations. Previous affiliations of Seock–Ah –A Im include Seoul National University.
Papers
More filters
Journal ArticleDOI
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
José Baselga,Seock–Ah –A Im,Hiroji Iwata,Javier Cortes,Michele De Laurentiis,Zefei Jiang,Carlos L. Arteaga,Walter Jonat,Mark Clemons,Yoshinori Ito,Ahmad Awada,Stephen Chia,Agnieszka Jagiełło-Gruszfeld,Barbara Pistilli,Ling Ming Tseng,Sara A. Hurvitz,Norikazu Masuda,Masato Takahashi,Peter Vuylsteke,Soulef Hachemi,Bharani Dharan,Emmanuelle di Tomaso,Patrick Urban,Cristian Massacesi,Mario Campone +24 more
TL;DR: This phase 3 study assessed the efficacy of the pan-PI3K inhibitor buparlisib plus fulvestrant in patients with advanced breast cancer, including an evaluation of the PI3K pathway activation status as a biomarker for clinical benefit.
Journal ArticleDOI
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial
Edith A. Perez,Ahmad Awada,Joyce O'Shaughnessy,Hope S. Rugo,Chris Twelves,Seock–Ah –A Im,Patricia Gómez-Pardo,Lee S. Schwartzberg,Véronique Diéras,Denise A. Yardley,David Potter,Audrey Mailliez,Alvaro Moreno-Aspitia,Jin Seok Ahn,Carol Zhao,Ute Hoch,Mary Tagliaferri,Alison L. Hannah,Javier Cortes +18 more
TL;DR: There was no significant difference in overall survival between groups and the frequency of cross-resistance and overlapping toxicities noted with many available drugs and the need for effective drugs in highly refractory disease, etirinotecan pegol may warrant further research in some subgroups of patients.
Journal ArticleDOI
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2
Mario Campone,Seock–Ah –A Im,Hiroji Iwata,Mark Clemons,Yoshinori Ito,Ahmad Awada,Stephen Chia,Agnieszka Jagiełło-Gruszfeld,Barbara Pistilli,Ling Min Tseng,Sara A. Hurvitz,Norikazu Masuda,Javier Cortes,Michele De Laurentiis,Carlos L. Arteaga,Zefei Jiang,Walter Jonat,Sylvie Le Mouhaer,Banu Sankaran,Laurence Bourdeau,Mona El-Hashimy,Dalila Sellami,José Baselga +22 more
TL;DR: Overall survival was assessed in the overall population and patients with known PI3K pathway status and OS by PIK3CA status in circulating tumour DNA (ctDNA) was an exploratory end-point; however, there was no statistical significance and more frequent grade III/IV adverse events were reported.
Journal ArticleDOI
Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.
Javier Cortes,Hope S. Rugo,Ahmad Awada,Chris Twelves,Edith A. Perez,Seock–Ah –A Im,Patricia Gómez-Pardo,Lee S. Schwartzberg,Véronique Diéras,Denise A. Yardley,David Potter,Audrey Mailliez,Alvaro Moreno-Aspitia,Jin Seok Ahn,Carol Zhao,Ute Hoch,Mary Tagliaferri,Alison L. Hannah,Joyce O'Shaughnessy +18 more
TL;DR: A significant improvement in survival in BCBM patients provides encouraging data for EP in this difficult-to-treat subgroup of patients, and a phase three trial of EP is underway.
Journal ArticleDOI
Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol
Hope S. Rugo,Javier Cortes,Ahmad Awada,Joyce O'Shaughnessy,Chris Twelves,Seock–Ah –A Im,Alison L. Hannah,Lin Lu,Sherwin K. B. Sy,Katie Caygill,Deborah D.A. Zajchowski,Darren W. Davis,Mary Tagliaferri,Ute Hoch,Edith A. Perez +14 more
TL;DR: CTC Top1 expression following EP treatment may identify patients with MBC most likely to have an OS benefit, and no significant associations with OS were observed in pretreatment samples for either group.